Publications, Pharmaceutical

Confirming bioequivalence for a generic tiotropium dry powder inhalers

Pharmacokinetic (PK) profiling is a central strategy for the demonstration of bioequivalence in generic dry powder inhaler development.

This paper describes a study in which in vitro testing under clinically relevant conditions, an in silico regional deposition model and a physiologically-based PK simulation model were used together to compare Test and Reference tiotropium products. In vitro testing detected significant batch to batch variability in the Reference product while in silico and PK data, in combination, highlighted the potential for variability in peripheral dose deposition to impact PK profile. The developed in silico model, once validated, has considerable potential to elucidate correlations between in vitro and in vivo data and help generic developers to establish and demonstrate robust bioequivalence.

Download Publication
25 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

8 Oct 2024

Understanding PBPK Modeling in OINDPs: Insights from Will Ganley

Publications, Pharmaceutical, Market Insights, Product Solutions

Read More
24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Product Solutions, Sustainability, Brand Differentiation, Market Insights

Read More
1 2 3 19
Back To Top